Top

Published in:

01-12-2011 | Research Paper

Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells

Authors: Kyoko Kushiro, Nomelí P. Núñez

Published in: Clinical & Experimental Metastasis | Issue 8/2011

Abstract

In 2009, malignant melanoma was responsible for approximately 9,000 deaths in the US. These deaths are often associated with aggressive metastasis to secondary sites such as the lungs. Epidemiological and animal studies suggest that obesity is a risk factor for melanoma. Others have shown that B16BL6 melanoma cells metastasize more aggressively in obese ob/ob than in lean mice. However, the mechanism by which obesity promotes B16BL6 melanoma metastasis in ob/ob mice has not been identified. In the present study, we used serum obtained from control and ob/ob leptin-deficient obese mice to determine if obese serum increases the aggressive phenotype of melanoma cells. Results showed that ob/ob serum has higher levels of resistin, insulin, tPAI1, IL-6, TNF-α, and MCP-1 compared to control serum. We showed that ob/ob serum increases the invasive ability of B16BL6 melanomas. To further determine the mechanism by which ob/ob serum increases the invasive ability of melanomas, we determined the effect of ob/ob and control serum on genes associated with the epithelial-to-mesenchymal transition (EMT). Cancer cells with a mesenchymal phenotype have a higher metastatic ability. Snai1 and Twist are genes that are strongly associated with EMT and metastasis of melanomas. Our results showed that ob/ob serum increases the expression of Snai1 and Twist. Moreover, ob/ob serum increased matrix metalloproteast 9 (MMP9) activity and decreased the expression of E-cadherin and the metastasis suppressor gene Kiss1. In summary, results suggest that obesity may increase the metastatic ability of melanoma by promoting a mesenchymal cell phenotype.

American Cancer Society (2009) Cancer facts and figures 2009. Atlanta, Georgia

Klimek VM, Wolchok JD, Chapman PB et al (2000) Systemic chemotherapy. Clin Plast Surg 27(3):451–461 ix-xPubMed

Dennis L, Lowe J, Lynch C et al (2008) Cutaneous melanoma and obesity in the agricultural health study. Ann Epidemiol 18(3):214–221PubMedCrossRef

Samanic C, Chow W, Gridley G et al (2006) Relation of body mass index to cancer risk in 362, 552 Swedish men. Cancer Causes Control 17(7):901–909PubMedCrossRef

Mori A, Sakurai H, Choo M et al (2006) Severe pulmonary metastasis in obese and diabetic mice. Int J Cancer 119(12):2760–2767PubMedCrossRef

Bonnomet A, Brysse A, Tachsidis A et al (2010) Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15(2):261–273PubMedCrossRef

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428PubMedCrossRef

Kang Y, Massagué J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118(3):277–279PubMedCrossRef

Foubert E, De Craene B, Berx G (2010) Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 12(3):206PubMedCrossRef

10.

Yang J, Mani SA, Donaher JL et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939PubMedCrossRef

11.

Przybylo JA, Radisky DC (2007) Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail’s pace. Int J Biochem Cell Biol 39(6):1082–1088PubMedCrossRef

12.

Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67PubMedCrossRef

13.

Steeg P (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3(1):55–63PubMedCrossRef

14.

Stafford L, Vaidya K, Welch D (2008) Metastasis suppressors genes in cancer. Int J Biochem Cell Biol 40(5):874–891PubMedCrossRef

15.

Albini A, Iwamoto Y, Kleinman H et al (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47(12):3239–3245PubMed

16.

Stattin P, Björ O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30(3):561–567PubMedCrossRef

17.

Ganapathi R, Grabowski D, Schmidt H et al (1987) Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells. Cancer Res 47(13):3464–3468PubMed

18.

Wallert and Provost Lab (2007) MMP zymogen gel assay protocol

19.

Lindström P (2007) The physiology of obese-hyperglycemic mice [ob/ob mice]. Sci World J 7:666–685

20.

Dubuc PU (1976) The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25(12):1567–1574PubMedCrossRef

21.

Stocks T, Lukanova A, Johansson M et al (2008) Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 32(2):304–314CrossRef

22.

Dissanayake SK, Wade M, Johnson CE et al (2007) The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 282(23):17259–17271PubMedCrossRef

23.

Ansieau S, Morel AP, Hinkal G et al (2010) TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 29(22):3173–3184PubMedCrossRef

24.

Jordà M, Olmeda D, Vinyals A et al (2005) Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci 118(Pt 15):3371–3385PubMedCrossRef

25.

Yan C, Wang H, Boyd D (2001) KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J Biol Chem 276(2):1164–1172PubMedCrossRef

26.

Shirasaki F, Takata M, Hatta N et al (2001) Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3–q23. Cancer Res 61(20):7422–7425PubMed

27.

Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375–379PubMedCrossRef

28.

Thiery J, Acloque H, Huang R et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMedCrossRef

29.

Kuphal S, Palm HG, Poser I et al (2005) Snail-regulated genes in malignant melanoma. Melanoma Res 15(4):305–313PubMedCrossRef

30.

Poser I, Domínguez D, de Herreros AG et al (2001) Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 276(27):24661–24666PubMedCrossRef

31.

Alonso SR, Tracey L, Ortiz P et al (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67(7):3450–3460PubMedCrossRef

32.

Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829PubMedCrossRef

33.

Pećina-Slaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3(1):17PubMedCrossRef

34.

Vesuna F, van Diest P, Chen JH et al (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367(2):235–241PubMedCrossRef

35.

Sullivan N, Sasser A, Axel A et al (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28(33):2940–2947PubMedCrossRef

36.

Wu Y, Deng J, Rychahou P et al (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15(5):416–428PubMedCrossRef

37.

Smith S, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9(4):253–264PubMedCrossRef

38.

Lee J, Miele M, Hicks D et al (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88(23):1731–1737PubMedCrossRef

Title: Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells
Authors: Kyoko Kushiro
Nomelí P. Núñez
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9418-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2011

Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells

Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver

Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases

High-dose ionizing radiation-induced hematotoxicity and metastasis in mice model

Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10

The effect of down regulation of calcineurin Aα by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer